Literature DB >> 24338045

Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".

Begoña Calvo1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24338045     DOI: 10.1007/s40264-013-0130-y

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  1 in total

Review 1.  Pharmacovigilance and biosimilars: considerations, needs and challenges.

Authors:  Nicole Casadevall; I Ralph Edwards; Thomas Felix; Peter R Graze; Jason B Litten; Bruce E Strober; David G Warnock
Journal:  Expert Opin Biol Ther       Date:  2013-03-26       Impact factor: 4.388

  1 in total
  1 in total

Review 1.  Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.

Authors:  Till Uhlig; Guro L Goll
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.